HLB
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
HLB - overview
Established
2000
Location
Seoul, -, South Korea
Primary Industry
Biotechnology
About
HLB Co. , Ltd. is a pharmaceutical company focusing on the development and commercialization of cutting-edge cancer therapies and healthcare solutions, dedicated to advancing patient outcomes in oncology. Founded in 2000, HLB Co.
, Ltd. is based in Ulsan, South Korea. The company specializes in pharmaceutical products and has successfully completed one deal as of July 31, 2017. HLB operates independently without any reported subsidiaries or parent companies.
The founder's background remains unspecified, and the company has not undergone significant strategic pivots or mergers. HLB Co. , Ltd. specializes in the development and commercialization of innovative pharmaceutical products, primarily targeting cancer therapies and advanced healthcare solutions.
Their flagship offering, Rivoceranib, is aimed at addressing critical unmet medical needs in oncology, specifically in liver cancer treatment. The company also focuses on researching CAR-T therapies, immune checkpoint inhibitors, and tailored healthcare products. These products serve healthcare settings, including hospitals and specialized oncology clinics, primarily catering to oncologists and healthcare providers across global markets such as Asia and North America. For the most recent fiscal year 2024, HLB Co.
, Ltd. reported a revenue of USD 49. 98 mn and an EBITDA of USD -82. 38 mn, indicating operational challenges despite their revenue generation efforts primarily through direct sales and partnerships with healthcare providers.
HLB Co. , Ltd. is strategically positioned for future growth through the development of new oncology products and their expansion into new geographic markets, including targeted initiatives in North America and Europe by 2026. The company aims to leverage the resources acquired from E&Investment's acquisition of HLB Co.
, Ltd. in July 2017 to support these growth initiatives. This planned expansion and product innovation is expected to enhance their market presence and improve healthcare outcomes.
Current Investors
E&Investment
Primary Industry
Biotechnology
Sub Industries
Biotechnology, Medical Devices & Equipment
Website
http://www.hlbkorea.com
Verticals
Manufacturing
Company Stage
Mature - Buyout
Total Amount Raised
Subscriber access only
HLB - timeline of key events
HLB - financials
| Fiscal Year Ended | Dec 31, 2011 | Dec 31, 2012 | Dec 31, 2013 | Dec 31, 2014 | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 69,517,784,606 | 51,673,996,760 | 31,451,550,190 | 37,185,747,890 | 38,460,683,507 | 30,138,866,814 | 23,006,912,167 | 86,185,983,416 | 38,420,748,245 | 56,177,400,696 | 69,825,991,454 | 179,707,913,112 | - | - | - |
| % Revenue Growth (YoY) | - | (25.7%) | (39.1%) | 18.2% | 3.4% | (21.6%) | (23.7%) | 274.6% | (55.4%) | 46.2% | 24.3% | 157.4% | - | - | - |
| EBITDA (USD) | 2,701,753,272 | (383,223,259) | (4,204,131,594) | 2,186,176,864 | (4,258,220,398) | (19,452,938,104) | (24,536,799,395) | (27,994,765,102) | (46,605,010,741) | (50,870,342,462) | (88,980,217,284) | (58,339,244,059) | - | - | - |
| Operating Income (USD) | 2,701,753,272 | (2,482,616,259) | (6,163,667,594) | 362,177,864 | (5,963,200,398) | (21,004,271,104) | (26,114,810,395) | (29,315,170,102) | (48,731,090,741) | (61,311,788,462) | (101,018,424,284) | (74,664,893,059) | - | - | - |
| Operating Margin | 3.9% | (4.8%) | (19.6%) | 1.0% | (15.5%) | (69.7%) | (113.5%) | (34.0%) | (126.8%) | (109.1%) | (144.7%) | (41.5%) | - | - | - |
| % EBITDA Margin | 3.9% | (0.7%) | (13.4%) | 5.9% | (11.1%) | (64.5%) | (106.6%) | (32.5%) | (121.3%) | (90.6%) | (127.4%) | (32.5%) | - | - | - |
| NET Income (USD) | (7,473,563,848) | (8,246,945,202) | (10,777,271,558) | (3,247,509,972) | 10,449,937,448 | (23,251,533,470) | (21,327,893,685) | 13,520,304,124 | (59,660,076,049) | (88,716,231,805) | (111,606,825,948) | (98,603,344,338) | - | - | - |
| % Net Margin | (10.8%) | (16.0%) | (34.3%) | (8.7%) | 27.2% | (77.1%) | (92.7%) | 15.7% | (155.3%) | (157.9%) | (159.8%) | (54.9%) | - | - | - |
HLB - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Add-on | Completed | PANAGENE Inc. | - | ||||||||
| Buyout | Completed | HLB | - |
Displaying 1 - 2 of 2
HLB - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.